Sean McCutcheon
Stock Analyst at Raymond James
(2.70)
# 2,136
Out of 5,055 analysts
11
Total ratings
54.55%
Success rate
6.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean McCutcheon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Strong Buy | $72 → $76 | $67.75 | +12.18% | 2 | Oct 17, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $5.63 | +113.14% | 1 | Jul 11, 2025 | |
| JANX Janux Therapeutics | Initiates: Outperform | $65 | $29.28 | +121.99% | 1 | Jul 11, 2025 | |
| CMPX Compass Therapeutics | Reinstates: Outperform | $9 | $4.83 | +86.34% | 1 | Jul 1, 2025 | |
| BDTX Black Diamond Therapeutics | Reinstates: Outperform | $11 | $4.01 | +174.31% | 1 | Jul 1, 2025 | |
| ENGN enGene Holdings | Initiates: Outperform | $23 | $8.53 | +169.64% | 1 | Nov 27, 2024 | |
| XNCR Xencor | Maintains: Strong Buy | $58 → $40 | $14.93 | +167.92% | 1 | Jun 14, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $92 → $70 | $66.44 | +5.36% | 2 | May 23, 2024 | |
| LEGN Legend Biotech | Initiates: Outperform | $86 | $30.29 | +183.92% | 1 | Mar 13, 2024 |
Revolution Medicines
Oct 17, 2025
Maintains: Strong Buy
Price Target: $72 → $76
Current: $67.75
Upside: +12.18%
Vir Biotechnology
Jul 11, 2025
Initiates: Outperform
Price Target: $12
Current: $5.63
Upside: +113.14%
Janux Therapeutics
Jul 11, 2025
Initiates: Outperform
Price Target: $65
Current: $29.28
Upside: +121.99%
Compass Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $9
Current: $4.83
Upside: +86.34%
Black Diamond Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $11
Current: $4.01
Upside: +174.31%
enGene Holdings
Nov 27, 2024
Initiates: Outperform
Price Target: $23
Current: $8.53
Upside: +169.64%
Xencor
Jun 14, 2024
Maintains: Strong Buy
Price Target: $58 → $40
Current: $14.93
Upside: +167.92%
Cytokinetics
May 23, 2024
Maintains: Outperform
Price Target: $92 → $70
Current: $66.44
Upside: +5.36%
Legend Biotech
Mar 13, 2024
Initiates: Outperform
Price Target: $86
Current: $30.29
Upside: +183.92%